Fibromyalgia
Fibromyalgia is, in one important sense, the pain condition that should fit psychedelics best. Its pain is not coming from damaged tissue but from a nervous system that amplifies pain signals, a problem of central processing wrapped in fatigue, poor sleep, brain fog and frequent depression. That is exactly the kind of brain-level, affectively-loaded problem the idea of "resetting" pain processing is meant for, which is why there is real research interest. But the evidence is still at the starting line. The headline human study tested psilocybin in just five people, without a control group; ketamine eases the pain briefly but a controlled trial found the benefit did not last; and most of the enthusiasm comes from patient surveys. A genuinely promising rationale, in other words, with barely any proof behind it yet.
How are psychedelics being studied for fibromyalgia? Fibromyalgia is a chronic condition of widespread pain, fatigue and sleep and mood difficulties, often resistant to standard treatments. Psychedelic research here is early and exploratory, testing whether psilocybin given in supervised sessions might change how the brain processes pain and ease the distress that accompanies it. Studies are small, and expectation effects are hard to separate from real benefit in conditions where pain is measured by self-report. The approach is supported sessions alongside usual care rather than a standalone cure. Blossom tracks the trials and papers behind fibromyalgia research so you can follow the evidence.
Data updated
Key Insights
- 1
Fibromyalgia is the textbook example of "nociplastic" pain: the hurt comes not from injured tissue but from a nervous system that amplifies pain signals, alongside fatigue, unrefreshing sleep, cognitive fog and high rates of depression and anxiety. That central, brain-level character is what makes the psychedelic rationale appealing here.
- 2
Because the problem is central rather than peripheral, fibromyalgia is arguably the best mechanistic fit in the whole pain family for the idea that psychedelics might "reset" how the brain processes pain. That is why a cluster of psilocybin fibromyalgia trials has appeared.
- 3
The reality check is the evidence. The lead human result is a 2025 open-label pilot of psilocybin-assisted therapy in just five people: it showed the treatment was safe and that participants reported feeling better, but with no control group it cannot show that it works. Larger controlled trials are only now recruiting.
- 4
Ketamine is mechanistically apt and does briefly reduce fibromyalgia pain, but a controlled trial found that a short infusion produced no lasting analgesia, which captures the field’s central problem: short-term relief that does not endure.
- 5
Much of the momentum is patient-driven, with surveys showing many people with fibromyalgia already use psychedelics, often microdosing, and report benefit. That is a real signal worth testing, but self-report is weak evidence. No psychedelic is approved for fibromyalgia, and standard drugs help modestly.
By the numbers
- 11
- Trials tracked
- 5
- Papers tracked
- 461
- Trial participants
as of June 2026
as of June 2026
as of June 2026
What is Fibromyalgia?
Fibromyalgia is a chronic condition of widespread musculoskeletal pain accompanied by fatigue, unrefreshing sleep, cognitive difficulties (often called "fibro fog") and, very commonly, depression and anxiety. It affects roughly 2 to 4% of adults, predominantly women. Crucially, its pain does not arise from damaged or inflamed tissue: fibromyalgia is the prototype of "nociplastic" pain, in which the central nervous system itself amplifies and sustains pain signals. Because it is a pain condition, it sits within our chronic pain family.
That central, brain-level character is exactly why fibromyalgia is interesting for psychedelics. Elsewhere in chronic pain, the honest story is that psychedelics are unlikely to fix pain coming from a damaged joint or nerve. Fibromyalgia is different: the problem is in how the nervous system processes and amplifies pain, layered with mood, sleep and cognitive symptoms, and that is precisely the kind of central, affectively-loaded target the "resetting brain processing" idea is built for. If psychedelics are going to help any pain condition, fibromyalgia is one of the more plausible candidates, which is what makes the gap between that plausibility and the actual evidence so striking.
Current Treatments
Standard care for fibromyalgia is multimodal and, at its best, genuinely helpful, though rarely curative. The strongest evidence is for non-drug approaches: graded exercise, cognitive behavioural therapy, education and sleep management. Several medicines are also approved or widely used, including pregabalin, duloxetine and milnacipran, which act on the nervous system rather than on inflammation. They help a meaningful minority of patients to a meaningful degree.
But the limitations are real and widely felt. The approved drugs work modestly and only for some, side effects are common, and many people with fibromyalgia remain in significant pain and distress despite trying the full toolkit. That large group of poorly-served patients, in a condition where the underlying problem is central rather than peripheral, is the reason a centrally-acting, brain-resetting approach attracts interest. What follows is investigational, and should be read against treatments that already offer modest help, not against nothing.
This report summarises what Blossom’s database shows about psychedelics and fibromyalgia, and it is an unusually clean example of a strong idea outrunning its evidence. Fibromyalgia is the prototype of pain that the brain itself amplifies, which makes it one of the most mechanistically appealing targets in the whole field for the notion that psychedelics might reset central pain processing. Yet the actual human evidence is a five-person open-label pilot, a controlled ketamine trial that came up short on durability, and a stack of patient surveys. The rationale is real; the proof is barely begun.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for fibromyalgia, and the studies described are early-stage research. Effective, if modest, treatments exist, exercise, cognitive behavioural therapy, sleep management and several approved medicines, and they are the right starting point. Fibromyalgia is real and often poorly served, but that is a reason to seek good care and, where possible, well-run trials, not to self-experiment with unregulated substances. If you are struggling with pain and low mood, please work with a clinician.
A word on scope and numbers. Blossom tracks only a handful of papers and a modest set of trials here, and many of the trials are still recruiting rather than reporting. The completed, results-bearing clinical evidence in fibromyalgia is very small, effectively one open-label psilocybin pilot and some older ketamine work. Read the counts as a field gearing up, not one that has delivered answers.
Why fibromyalgia fits the theory
The reason this topic is worth taking seriously starts with what fibromyalgia is. It is the clearest clinical example of nociplastic pain, pain generated and amplified by the central nervous system rather than by tissue damage or inflammation. People with fibromyalgia have widespread pain, but also disrupted sleep, profound fatigue, cognitive fog and, very often, depression and anxiety, a whole-system, brain-centred picture. Conventional painkillers, which target peripheral pain and inflammation, work poorly precisely because the problem is not peripheral.
That is what makes psychedelics conceptually interesting here in a way they are not for, say, arthritis. The central hypothesis of psychedelic pain research, that these drugs might alter how the brain processes and amplifies pain, and simultaneously ease the depression and catastrophising that accompany it, maps unusually well onto a condition that is itself fundamentally about central amplification and emotional load. If the theory is right anywhere in chronic pain, fibromyalgia is one of the places it should show up. That is a reason for genuine interest, and also a reason to be especially careful not to let the elegance of the fit substitute for data.
The lead study, in full and honest proportion
The first and most important human study is a 2025 open-label pilot of psilocybin-assisted therapy for fibromyalgia[1], from a respected academic collaboration. Participants received two psilocybin doses with preparation and integration therapy. The results, on their own terms, were encouraging: the treatment was safe and well tolerated, with only transient rises in blood pressure and heart rate and some short-lived headaches, and participants reported improvements across many fibromyalgia symptoms. As a demonstration that psilocybin can be given safely to this group and that benefit is plausible, it does its job.
But the proportion matters enormously. The study enrolled five people. It had no control group and no blinding, so there is no way to separate a real drug effect from expectation, the natural ups and downs of fibromyalgia, or the considerable attention and support participants received. In a condition where symptoms fluctuate and where placebo responses are typically large, a five-person open-label result is a starting point, not a finding. The right way to read it is that it justifies the controlled trials now recruiting, including larger, multi-centre and biomarker-based studies, and that those trials, not this pilot, will tell us whether psilocybin treats fibromyalgia.
Ketamine: the mechanism works, the durability does not
Ketamine offers a useful, sobering counterpoint, because it is the one psychedelic-adjacent drug with a longer fibromyalgia track record. Its rationale is excellent: by blocking the NMDA receptor central to pain "wind-up" and sensitisation, it targets the very mechanism thought to drive fibromyalgia, and it does reduce pain acutely. On paper, it should work. In practice, a controlled trial found that a short-term S-ketamine infusion produced no lasting analgesic effect[2].
That result is a warning worth heeding as the psilocybin trials proceed. It shows that hitting the right central mechanism, even convincingly, does not guarantee durable benefit, and that transient relief, which is easy to mistake for success in an open-label or short-term study, can fade completely. Fibromyalgia has a long history of treatments that looked promising on mechanism and disappointed in durability. The ketamine experience is a reminder to judge the coming psilocybin trials on lasting, controlled outcomes rather than on short-term impressions.
The patient community, and weak but real signals
One feature sets fibromyalgia apart from most pages here: a large, organised, self-treating patient community. Surveys of people with fibromyalgia find that many already use psychedelics, often by microdosing, and report benefit[3], and wider survey work suggests perceived analgesic effects of psychedelics across several chronic pain conditions[4]. There are also vivid individual accounts, such as a case report of long-lasting relief after changa[5].
These deserve to be taken seriously as a reason to research, and treated cautiously as evidence. Surveys and case reports are uncontrolled and self-selected; the people who try psychedelics and report back are not a random sample, and those who benefit are more likely to share. They generate a real, testable hypothesis, that low-dose or full-dose psychedelics help fibromyalgia, but they cannot confirm it, and microdosing in particular, popular as it is in this community, has essentially no controlled support for pain. The honest stance respects the patient experience enough to insist on testing it properly.
Reading this honestly
So where does fibromyalgia sit? It is one of the most promising rationales in psychedelic pain research and one of the least proven, an unusually pure case of theory ahead of evidence. The mechanism fits: this is central, brain-amplified pain wrapped in mood and cognitive symptoms, exactly what a central-resetting treatment should suit. The data do not yet match: a five-person open-label pilot, a ketamine trial that confirmed the mechanism but not durability, and a community of patients reporting benefit they have not been able to test. For people living with fibromyalgia, the truthful message is genuinely hopeful and genuinely unfinished: this may prove to be one of the better psychedelic pain indications, the trials that could show it are now under way, and until they report, the proven if modest treatments, exercise, therapy and approved medicines, remain where care should sit, and unregulated self-treatment is not a safe shortcut.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Fibromyalgia.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin The lead candidate, with the strongest mechanistic rationale and the most trial activity, but only the earliest evidence. A 2025 open-label pilot in just five people found psilocybin-assisted therapy safe and reported broad symptom improvement, but had no control group. Several controlled trials are now recruiting. Promising and well-motivated; not yet shown in a controlled study to work. | Small | Low | Low |
| Ketamine Mechanistically apt (it acts on the NMDA receptor implicated in central sensitisation) and can reduce fibromyalgia pain acutely. But durability is the problem: a controlled trial found that a short S-ketamine infusion produced no lasting analgesia. Useful as a probe of the mechanism; not an effective standalone treatment on current evidence. | Small | Low | Low |
| LSD Represents the patient-led, low-dose end of this field. Many people with fibromyalgia report microdosing LSD or using other serotonergic psychedelics for pain, and isolated case reports (such as long-lasting relief after changa) exist. This is real-world interest and anecdote, not controlled evidence, and should be read as hypothesis-generating only. | Small | Very Low | Low |
Psilocybin and Fibromyalgia
Psilocybin is the focus of serious fibromyalgia research, and the rationale is genuinely strong: a centrally-amplified pain condition, wrapped in depression, anxiety and cognitive symptoms, is close to an ideal target for a treatment thought to act on central pain processing and emotional pain together. The first human test is a 2025 open-label pilot of psilocybin-assisted therapy in adults with fibromyalgia[1], which gave participants two doses with psychological support and found the treatment safe and well tolerated, with participants reporting improvements across many fibromyalgia symptoms.
The decisive limitation is size and design. That pilot enrolled only five people, with no control group and no blinding, which is exactly the setup in which expectation and natural fluctuation can produce apparent benefit. It is a legitimate proof-of-concept, it establishes that psilocybin can be given safely in this population and that a controlled trial is worth doing, but it cannot show that psilocybin actually treats fibromyalgia. Several properly controlled trials, including multi-centre studies, are now recruiting, and those, not the pilot, will determine whether the strong rationale holds up.
Ketamine and Fibromyalgia
Ketamine has the clearest mechanistic claim in fibromyalgia, because it blocks the NMDA receptor that is central to the "wind-up" and sensitisation thought to drive the condition, and it does measurably reduce fibromyalgia pain in the short term. For a disorder of central amplification, that is a logical place to intervene.
The problem is that the relief does not last. A controlled trial found that a short-term S-ketamine infusion produced no long-term analgesic effect in fibromyalgia[1], which neatly captures the recurring difficulty with ketamine across chronic pain: a real but transient effect that fades, leaving an open-ended commitment to repeated infusions with no durable gain. Trials of repeated dosing and of esketamine continue, but on current evidence ketamine is better understood as a confirmation that the central mechanism matters than as a treatment that solves it.
LSD and Fibromyalgia
Beyond the formal trials, fibromyalgia has an unusually active patient-led psychedelic scene, and LSD stands in here for that low-dose, self-directed end of the field. Surveys of people with fibromyalgia find that a notable share already use psychedelics, frequently by microdosing, and many report benefit for pain and mood[1], echoing broader survey work on the perceived analgesic effects of psychedelics in chronic pain[2].
These reports matter, both as a signal worth testing and because they describe what patients are actually doing, but they are weak evidence: uncontrolled, self-selected and prone to over-reporting benefit. The same caution applies to striking individual stories, such as a case report of long-lasting pain relief after the psychedelic brew changa[3]. They are the reason to run trials, not a substitute for them, and microdosing for fibromyalgia remains an untested, if popular, idea.
Clinical Outlook
The near-term outlook is unusually well-defined for such an early field: a clear, plausible hypothesis is about to meet its first proper tests. Multiple controlled psilocybin trials in fibromyalgia are recruiting, including multi-centre studies and work using brain-imaging biomarkers to probe how, and whether, psilocybin changes central pain processing. There is even early interest in MDMA-assisted therapy for the condition. Within a few years, this should move from "strong rationale, almost no data" to a real answer in at least one direction.
The realistic outlook is cautious optimism with a specific risk. The risk is that fibromyalgia’s combination of a compelling mechanism, a large and underserved patient group, and an enthusiastic self-treating community makes it unusually easy to over-claim, to read a five-person open-label pilot and a wave of survey reports as if they were proof. They are not. The honest position is that fibromyalgia may turn out to be one of the better psychedelic pain indications precisely because its pain is central, and that this remains a hypothesis awaiting the controlled trials now under way, with modestly-effective conventional treatment the right course in the meantime.
Industrial Landscape
The research effort is mostly academic, led by pain and psychiatry groups at universities (the psilocybin pilot came from a Michigan, Ohio State and Johns Hopkins collaboration) and motivated by the poor options available for a common, disabling and historically dismissed condition. A few companies are exploring psychedelics and novel agents for centralised pain, and the patient community, long frustrated by being doubted or under-treated, is an unusually engaged and motivated stakeholder.
For an honest broker, fibromyalgia is a place to honour both the promise and the patients without inflating either. The mechanistic case is one of the better ones in pain, and the people involved have often been let down by medicine and deserve real research rather than dismissal or hype. The responsible message is to take the central-pain rationale seriously, to support and await the controlled trials, to treat the patient-survey enthusiasm as a reason to investigate rather than as evidence of efficacy, and to be clear that, for now, psychedelics are an investigational hope and the proven, if modest, treatments remain the foundation.
Quick Indicators
Related Topics
Organisations
Search →MAPS
MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Maastricht University
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
Beijing Sanbo Brain Hospital
Beijing Sanbo Brain Hospital (首都医科大学三博脑科医院) is a leading private specialised neurological hospital founded in 2004, affiliated with Capital Medical University as its Eleventh Clinical School, with 256 beds dedicated to neurosurgery, epilepsy, cerebrovascular disease, and functional neuroscience. Its anesthesiology department participates in multi-centre trials investigating ketamine and related anesthetic agents in neurosurgical settings.
Beijing Tiantan Hospital
China's premier neurology and neurosurgery hospital, affiliated with Capital Medical University and home to the National Clinical Research Center for Neurological Diseases. Conducted the PASSION trial — a randomized, placebo-controlled study of intraoperative ketamine for depression in neurosurgical patients.
Centre Hospitalier Universitaire de Charleroi
University hospital in Charleroi, Belgium affiliated with the Université Libre de Bruxelles. Participates in clinical trials for psychiatric and neurological conditions, including studies in the emerging area of esketamine and rapid-acting antidepressant therapies.
Grand Hôpital de Charleroi
Grand Hôpital de Charleroi (GHdC) is a large multi-site hospital system with six hospitals in Charleroi, Wallonia, Belgium, listed as a clinical research center on the European Clinical Trials Information Network. The hospital sponsors ESKEFIB (NCT04436250), a prospective randomized double-blind trial evaluating S-ketamine as a treatment for fibromyalgia, contributing to Belgium's growing ketamine clinical research infrastructure.
Spaulding Rehabilitation Hospital
Spaulding Rehabilitation Hospital is a leading rehabilitation hospital in Boston, Massachusetts, affiliated with the Mass General Brigham health system and home to the Scott Schoen and Nancy Adams Discovery Center for Chronic Pain Recovery. It is pioneering psychedelic research in pain medicine through the first clinical trial of MDMA-assisted therapy for fibromyalgia, which uses hyperscan neuroimaging to investigate how MDMA influences brain-to-brain dynamics between patient and therapist to produce analgesia, in collaboration with PharmAla Biotech.
University of Alabama at Birmingham
Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.
Wilderman Medical Clinic
A private medical clinic in Thornhill, Ontario, Canada, specializing in pain management and ketamine-assisted therapy for treatment-resistant pain and mood disorders. Founded by Dr. Igor Wilderman, the clinic conducts investigator-initiated clinical trials and combines conventional and advanced interventional pain management approaches in a multidisciplinary clinical setting.
People
Search →Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Gonzalo Ona
Clinical Researcher in Psychedelic Psychopharmacology
Notable for epidemiological and clinical research on ayahuasca use, safety and wellbeing outcomes, and exploratory pharmacological work on 5‑MeO‑DMT and psychedelic interactions.
Johannes Ramaekers
Professor of Psychopharmacology
Leading expert in behavioral toxicology and the impact of psychoactive substances on human performance and cognition.
Amanda Feilding
Executive Director and Founder
Innocative figure in psychedelic research and founder of the Beckley Foundation.
Kim Kuypers
Associate Professor of Psychopharmacology
Kuypers is a leading figure in psychedelic research, particularly in understanding the effects of psychedelics on pain perception and mental health.
Nathalie Mason
Clinical Researcher
Notable for experimental and early-phase clinical studies characterising the subjective, physiological and potential therapeutic effects of classical psychedelics and novel tryptamines in humans.
James Guss
Clinical Researcher and Psychotherapist
A prominent contributor to contemporary clinical and qualitative research on psilocybin-assisted psychotherapy, particularly in cancer-related psychiatric and existential distress and therapist training/integration.
Jordan Aday
Clinical Researcher
Notable for conducting naturalistic and survey-based studies characterising psychological, social and therapeutic effects of ayahuasca and other psychedelic practices, and for examining practitioner behaviour and treatment-access issues in the psychedelic field.
Kevin Boehnke
Assistant Professor of Anesthesiology; Associate Director of the Michigan Psychedelic Center
Notable for contributions to naturalistic and survey-based research on psychedelic use, including attitudes toward treatment cost and non-hallucinogenic alternatives, substance-use changes after psychedelic experiences, and psychedelic use among patient groups such as people with fibromyalgia.
Pamela Kryskow
Clinical Instructor, Faculty of Medicine at the University of British Columbia; Adjunct Professor at Vancouver Island University; Medical Lead at Roots to Thrive
She is a physician-researcher contributing to clinical and observational research on psychedelic-assisted therapy, microdosing, and chronic pain, helping build the evidence base for emerging psychedelic medicine.
George Mashour
Professor of Anesthesiology and Pharmacology at the University of Michigan; Founding Director of the Michigan Psychedelic Center
He is a leading neuroscientist in psychedelic and consciousness research whose work bridges basic neurobiology, human neuroimaging, and clinical translation.
Connected Evidence
The latest clinical data and verified academic findings associated with Fibromyalgia.